stockrowBio-Rad Laboratories, Inc.
BIO Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.8%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
Follow BIO
Alert me
Bio-Rad Laboratories, Inc. (BIO) Shares outstanding
Bio-Rad Laboratories, Inc.'s shares outstanding at the end of fiscal 2025 was $27.3M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $26.9M. Over the past ten years it has ranged from $27.3M (fiscal 2025) to $30.2M (fiscal 2018) — the current reading is the lowest in ten years. Bio-Rad Laboratories, Inc. ranks 93rd of 147 Medical Devices companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $27.3M | (3.31%) |
| FY2024 | $28.2M | (3.41%) |
| FY2023 | $29.2M | (1.93%) |
| FY2022 | $29.8M | (1.40%) |
| FY2021 | $30.2M | 0.16% |
| FY2020 | $30.2M | (0.08%) |
| FY2019 | $30.2M | (0.15%) |
| FY2018 | $30.2M | 0.65% |
| FY2017 | $30.0M | 1.31% |
| FY2016 | $29.6M | 0.81% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $26.9M | 0.49% |
| Jun 2026 | $26.8M | (0.53%) |
| Mar 2026 | $27.0M | (1.18%) |
| Dec 2025 | $27.3M | 1.33% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $449.4M |
| BRKR Bruker Corporation compare | $152.5M |
| GMED Globus Medical, Inc. compare | $136.0M |
| TXG 10x Genomics compare | $130.0M |
| PODD Insulet Corporation compare | $69.5M |
| GKOS Glaukos Corporation compare | $61.2M |
| PEN Penumbra, Inc. compare | $39.6M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $26.9M |
| BIO Bio-Rad Laboratories, Inc. | $26.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on BIO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement